Roche’s VENTANA PD-L1 Assay receives FDA approval as a companion diagnostic to identify lung cancer patients eligible for Tecentriq (atezolizumab)
The VENTANA PD-L1 (SP263) Assay helps determine which non-small cell lung cancer patients may benefit from treatment with Tecentriq immunotherapy based on the results of the Phase III IMpower010 study